Observational studyPituitary2014
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.
Observational study in Pituitary, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults.The Cochrane database of systematic reviews · 2024Pooled it
- Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review.Endocrine · 2023Pooled it
- Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.Advances in therapy · 2021Pooled it
- Clinical and economic burden among older adults with acromegaly in the United States.Journal of comparative effectiveness research · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era.Endocrine · 2021Article
- Review of Contemporary Self-Assembled Systems for the Controlled Delivery of Therapeutics in Medicine.Nanomaterials (Basel, Switzerland) · 2021Review
- Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis.Endocrine · 2018Observational
- Review
- Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.BMC endocrine disorders · 2017Article
- Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.Pituitary · 2016Article
- Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues.Endocrine connections · 2016Article
- Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.European journal of endocrinology · 2016Observational
- New therapeutic agents for acromegaly.Nature reviews. Endocrinology · 2016Review
- Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.European journal of endocrinology · 2015Article
- The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.Patient preference and adherence · 2015Article
- Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Drugs · 2014Review
- Patient-focussed outcomes in acromegaly.Pituitary · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
Lanreotide depot (LD; commercial name Somatuline(®) Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide. In recent clinical trials, LD was found to be suitable for self or partner administration, avoiding the need to travel to a medical facility. The Somatuline(®) Depot for Acromegaly (SODA) study is an ongoing, multicenter, observational study in the US investigating the efficacy, safety, convenience and symptom relief provided by LD in patients with acromegaly. Sub-analyses explore outcomes according to who administered the injection: patient, partner, healthcare provider (HCP) or a combination. Data reported here reflect one year of patient experience. Patients are eligible for inclusion if they have a diagnosis of acromegaly, are treated with LD and can give signed informed consent. Baseline data include patient demographics, previous acromegaly treatment and investigations, GH and IGF-I levels, LD dose and dose adjustment frequency. Symptom frequency, injection pain and treatment convenience are assessed using patient-reported questionnaires. As of 18 April 2012, 166 patients had enrolled in SODA. Most (72 %) achieved normal IGF-I levels after 12 months of LD treatment. Disease control was similar in self or partner injectors and in patients who received injections from their HCP, although self or partner injecting was deemed more convenient. LD was well-tolerated irrespective of who performed the injection. Self injection led to more injection-site reactions, but this did not increase the rate of treatment interruption. Acromegaly symptoms remained stable. Biochemical, safety and convenience data support the clinical validity of injecting LD at home.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.